The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro antimicrobial assays and ex vivo post-mortem brain tissue experiments.
PubMed 20209079 · doi:10.1371/journal.pone.0009505
What was done
Researchers evaluated the antimicrobial properties of amyloid beta-protein (Abeta) using in vitro comparative assays against the human antimicrobial peptide LL-37 across eight clinically relevant microorganisms. They also compared the antimicrobial activity of post-mortem whole brain homogenates from patients with Alzheimer's disease (AD) against age-matched non-AD controls, tested correlations with tissue Abeta levels, and performed immunodepletion assays using anti-Abeta antibodies.
What was found
The abstract reports no numerical values. In vitro, Abeta showed antimicrobial activity against eight microorganisms with potency equivalent to or greater than LL-37. AD brain homogenates showed significantly higher antimicrobial activity than age-matched non-AD controls, which correlated with tissue Abeta levels and was ablated by immunodepleting Abeta with specific antibodies.
Why it matters
These findings suggest that Abeta may function physiologically as an antimicrobial peptide within the innate immune system rather than merely being a toxic catabolic byproduct, challenging standard assumptions underlying Alzheimer's disease therapeutics.
Limits
The abstract provides no quantitative effect sizes, sample sizes for human brain tissue specimens, or statistical values. Because the study relies on in vitro assays and ex vivo brain homogenates, in vivo antimicrobial efficacy, physiological relevance in living humans, and long-term consequences of Abeta clearance therapies were not directly measured.
Cited by
- supports Amyloid aggregates have been shown in laboratory studies to create holes in bacterial cell membranes, leading to the hypothesis that amyloid functions as an antibacterial protein.